Zacks Investment Research lowered shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a buy rating to a hold rating in a research note published on Wednesday, May 2nd.
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
Several other brokerages also recently issued reports on BCRX. HC Wainwright restated a buy rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, January 23rd. Royal Bank of Canada raised shares of BioCryst Pharmaceuticals from a sector perform rating to an outperform rating and set a $6.00 target price on the stock in a report on Tuesday, January 2nd. BidaskClub raised shares of BioCryst Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, March 6th. Finally, ValuEngine raised shares of BioCryst Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $8.36.
Shares of BCRX stock opened at $5.90 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.38 and a quick ratio of 1.38. The company has a market cap of $590.33 million, a price-to-earnings ratio of -7.56 and a beta of 2.60. BioCryst Pharmaceuticals has a 12-month low of $5.85 and a 12-month high of $6.01.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.10). The company had revenue of $3.98 million for the quarter, compared to analyst estimates of $10.20 million. BioCryst Pharmaceuticals had a negative return on equity of 114.36% and a negative net margin of 392.09%. sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.87 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Eversept Partners LLC bought a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $974,000. Virtus Fund Advisers LLC bought a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $349,000. Teacher Retirement System of Texas bought a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $155,000. BlackRock Inc. increased its stake in BioCryst Pharmaceuticals by 15.0% in the fourth quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock valued at $37,386,000 after acquiring an additional 993,100 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in BioCryst Pharmaceuticals by 55.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 496,792 shares of the biotechnology company’s stock valued at $2,440,000 after acquiring an additional 176,714 shares during the last quarter. 91.97% of the stock is currently owned by institutional investors.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.